Giovanni Cimmino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4216629/publications.pdf

Version: 2024-02-01

78 papers 2,148 citations

236833 25 h-index 243529 44 g-index

87 all docs

87 docs citations

87 times ranked 3296 citing authors

#	Article	IF	CITATIONS
1	Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. Journal of Thrombosis and Thrombolysis, 2022, 53, 739-749.	1.0	5
2	Vitamin D Inhibits IL-6 Pro-Atherothrombotic Effects in Human Endothelial Cells: A Potential Mechanism for Protection against COVID-19 Infection?. Journal of Cardiovascular Development and Disease, 2022, 9, 27.	0.8	14
3	Pharmacokinetic determinants for the right dose of antiarrhythmic drugs. Expert Opinion on Drug Metabolism and Toxicology, 2022, , 1-12.	1.5	1
4	Asymptomatic Stroke in the Setting of Percutaneous Non-Coronary Intervention Procedures. Medicina (Lithuania), 2022, 58, 45.	0.8	1
5	Pathophysiology and mechanisms of Acute Coronary Syndromes: atherothrombosis, immune-inflammation, and beyond. Expert Review of Cardiovascular Therapy, 2022, 20, 351-362.	0.6	4
6	Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells. Vascular Pharmacology, 2021, 137, 106822.	1.0	10
7	Transcatheter Aortic Valve Implantation: The New Challenges of Cardiac Rehabilitation. Journal of Clinical Medicine, 2021, 10, 810.	1.0	6
8	Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding. Medicina (Lithuania), 2021, 57, 444.	0.8	7
9	Peripheral Artery Disease and Abdominal Aortic Aneurysm: The Forgotten Diseases in COVID-19 Pandemic. Results from an Observational Study on Real-World Management. Medicina (Lithuania), 2021, 57, 672.	0.8	1
10	Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports. Journal of Cardiovascular Pharmacology, 2021, 78, e20-e29.	0.8	17
11	Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization. International Journal of Environmental Research and Public Health, 2021, 18, 102.	1.2	15
12	Oxidized low-density lipoproteins induce tissue factor expression in T-lymphocytes via activation of lectin-like oxidized low-density lipoprotein receptor-1. Cardiovascular Research, 2020, 116, 1125-1135.	1.8	15
13	Vitamin D inhibits Tissue Factor and CAMs expression in oxidized low-density lipoproteins-treated human endothelial cells by modulating NF-κB pathway European Journal of Pharmacology, 2020, 885, 173422.	1.7	17
14	The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 2020, 9, 3926.	1.0	12
15	Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. Journal of Thrombosis and Thrombolysis, 2020, 50, 468-472.	1.0	20
16	Antiplatelet Therapy in Acute Coronary Syndromes. Lights and Shadows of Platelet Function Tests to Guide the Best Therapeutic Approach. Current Vascular Pharmacology, 2020, 18, 262-272.	0.8	13
17	Radial pseudoaneurysm in elderly: a rare event with undefinied therapeutical approach. A case report and literature review. Monaldi Archives for Chest Disease, 2019, 89, .	0.3	4
18	Cognitive Function and Atrial Fibrillation: From the Strength of Relationship to the Dark Side of Prevention. Is There a Contribution from Sinus Rhythm Restoration and Maintenance?. Medicina (Lithuania), 2019, 55, 587.	0.8	21

#	Article	IF	CITATIONS
19	Effects of Hypobaric Hypoxia on Endothelial Function and Adiponectin Levels in Airforce Aviators. High Altitude Medicine and Biology, 2019, 20, 165-170.	0.5	1
20	Management and 1â€Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	1.6	44
21	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. Circulation, 2019, 139, 787-798.	1.6	60
22	Time trends in antithrombotic management of patients with atrial fibrillation treated with coronary stents: Results from TALENTâ€AF (The internAtionaL stENT – Atrial Fibrillation study) multicenter registry. Clinical Cardiology, 2018, 41, 470-475.	0.7	15
23	Relationship between Pregnancy-associated Plasma Protein-A and tissue factor levels in the coronary circulation of patients with acute coronary syndrome. International Journal of Cardiology, 2018, 258, 14-16.	0.8	4
24	Splicing of platelet resident pre-mRNAs upon activation by physiological stimuli results in functionally relevant proteome modifications. Scientific Reports, 2018, 8, 498.	1.6	65
25	Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis. Cardiovascular Diagnosis and Therapy, 2018, 8, 581-593.	0.7	43
26	Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascular Pharmacology, 2018, 111, 62-70.	1.0	38
27	Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. Diseases (Basel, Switzerland), 2018, 6, 22.	1.0	10
28	Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy. Acta Myologica, 2018, 37, 227-231.	1.5	0
29	The role of the atrial electromechanical delay in predicting atrial fibrillation in beta-thalassemia major patients. Journal of Interventional Cardiac Electrophysiology, 2017, 48, 147-157.	0.6	20
30	Nobiletin inhibits oxidized-LDL mediated expression of Tissue Factor in human endothelial cells through inhibition of NF-κB. Biochemical Pharmacology, 2017, 128, 26-33.	2.0	23
31	Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long†Term Outcome. Journal of Interventional Cardiology, 2017, 30, 5-15.	0.5	8
32	Antiplatelet Therapy for Non–ST-Segment Elevation Myocardial Infarction in Complex "Real―Clinical Scenarios: A Consensus Document of the "Campania NSTEMI Study Group― Angiology, 2017, 68, 598-607.	0.8	1
33	Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque. Current Cardiology Reviews, 2017, 13, 110-117.	0.6	31
34	Upregulation of TH/IL-17 Pathway-Related Genes in Human Coronary Endothelial Cells Stimulated with Serum of Patients with Acute Coronary Syndromes. Frontiers in Cardiovascular Medicine, 2017, 4, 1.	1.1	28
35	The nuclear receptor $\mathrm{ER}\hat{\mathbf{l}}^2$ engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading. Genome Biology, 2017, 18, 189.	3.8	63
36	Role of circulating factors in cardiac aging. Journal of Thoracic Disease, 2017, 9, S17-S29.	0.6	14

3

#	Article	IF	Citations
37	Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches. Current Vascular Pharmacology, 2017, 15, 197-206.	0.8	6
38	Expression of functional tissue factor in activated T-lymphocytes in vitro and in vivo: A possible contribution of immunity to thrombosis?. International Journal of Cardiology, 2016, 218, 188-195.	0.8	24
39	Evolving Concepts in LDL-Lowering Strategies: Are We There?. Journal of Clinical & Experimental Cardiology, 2016, 7, .	0.0	2
40	Increased heterogeneity of ventricular repolarization in myotonic dystrophy type 1 population. Acta Myologica, 2016, 35, 100-106.	1.5	8
41	Voltage-directed cavo-tricuspid isthmus ablation using a novel ablation catheter mapping technology in a myotonic dystrophy type I patient. Acta Myologica, 2016, 35, 109-113.	1.5	3
42	Role of Tissue Factor in the Coagulation Network. Seminars in Thrombosis and Hemostasis, 2015, 41, 708-717.	1.5	22
43	The adipokine apelin-13 induces expression of prothrombotic tissue factor. Thrombosis and Haemostasis, 2015, 113, 363-372.	1.8	18
44	Activating stimuli induce platelet microRNA modulation and proteome reorganisation. Thrombosis and Haemostasis, 2015, 114, 96-108.	1.8	40
45	Reactive oxygen species induce a procoagulant state in endothelial cells by inhibiting tissue factor pathway inhibitor. Journal of Thrombosis and Thrombolysis, 2015, 40, 186-192.	1.0	19
46	High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need. Translational Medicine @ UniSa, 2015, 12, 29-40.	0.8	4
47	A Fatal Case of Endocarditis on CoreValve ReValving System Caused by Enterococcus faecium Complicated by latrogenic Pancytopenia and Subacute Disseminated Intravascular Coagulation. Journal of Heart Valve Disease, 2015, 24, 130-2.	0.5	2
48	Local cytokine production in patients with Acute Coronary Syndromes: A look into the eye of the perfect (cytokine) storm. International Journal of Cardiology, 2014, 176, 227-229.	0.8	13
49	Platelet Biology and Receptor Pathways. Journal of Cardiovascular Translational Research, 2013, 6, 299-309.	1.1	64
50	C-reactive protein induces expression of matrix metalloproteinase-9: A possible link between inflammation and plaque rupture. International Journal of Cardiology, 2013, 168, 981-986.	0.8	46
51	High-density lipoproteincholesterol, reverse cholesterol transport, and cardiovascular risk: a tale of genetics?. Neurology International, 2013, 3, .	0.2	0
52	Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. European Heart Journal, 2012, 33, 264-273.	1.0	36
53	Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-type. Atherosclerosis, 2012, 220, 72-77.	0.4	95
54	The complex puzzle underlying the pathophysiology of acute coronary syndromes: from molecular basis to clinical manifestations. Expert Review of Cardiovascular Therapy, 2012, 10, 1533-1543.	0.6	14

#	Article	IF	Citations
55	Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term. Thrombosis and Haemostasis, 2012, 108, 1246-1248.	1.8	18
56	The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion. International Journal of Cardiology, 2011, 147, 428-432.	0.8	55
57	Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. International Journal of Cardiology, 2011, 153, 256-261.	0.8	24
58	C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes. International Journal of Cardiology, 2011, 152, 7-12.	0.8	39
59	Transcoronary Th-17 lymphocytes and acute coronary syndromes: new evidence from the crime scene?. International Journal of Cardiology, 2011, 153, 215-216.	0.8	11
60	Adeno-associated Virus Serotype 8 ApoA-I Gene Transfer Reduces Progression of Atherosclerosis in ApoE-KO Mice: Comparison of Intramuscular and Intravenous Administration. Journal of Cardiovascular Pharmacology, 2011, 57, 325-333.	0.8	9
61	Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited?. Internal and Emergency Medicine, 2011, 6, 29-34.	1.0	21
62	Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. European Heart Journal, 2011, 32, 316-325.	1.0	60
63	The missing link between atherosclerosis, inflammation and thrombosis: is it tissue factor?. Expert Review of Cardiovascular Therapy, 2011, 9, 517-523.	0.6	44
64	Pathophysiology of Vulnerability Caused by Thrombogenic (Vulnerable) Blood., 2011,, 53-66.		0
65	Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. European Heart Journal, 2010, 31, 2049-2057.	1.0	56
66	Contrast-Enhanced Ultrasound Imaging Detects Intraplaque Neovascularization in an Experimental Model of Atherosclerosis. JACC: Cardiovascular Imaging, 2010, 3, 1256-1264.	2.3	44
67	Upâ€regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoAâ€l _{Milano} . Journal of Cellular and Molecular Medicine, 2009, 13, 3226-3235.	1.6	46
68	Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay. Journal of Thrombosis and Haemostasis, 2009, 7, 894-897.	1.9	35
69	Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. Atherosclerosis, 2009, 202, 185-191.	0.4	19
70	Genesis and Dynamics of Atherosclerotic Lesions: Implications for Early Detection. Cerebrovascular Diseases, 2009, 27, 38-47.	0.8	55
71	Safe and Sustained Overexpression of Functional Apolipoprotein A-I/High-density Lipoprotein in Apolipoprotein A-I–null Mice by Muscular Adeno-associated Viral Serotype 8 Vector Gene Transfer. Journal of Cardiovascular Pharmacology, 2009, 54, 405-411.	0.8	10
72	Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration. Journal of the American College of Cardiology, 2008, 51, 1104-1109.	1.2	122

#	Article	lF	CITATIONS
73	TF Independent Potentiation of FVIIa Activity in CAD Plasma: An Assessment Using Two Chromogenic Assays Blood, 2008, 112, 1820-1820.	0.6	0
74	Early Metoprolol Administration Before Coronary Reperfusion Results in Increased Myocardial Salvage. Circulation, 2007, 115, 2909-2916.	1.6	142
75	Patients With Acute Coronary Syndrome Show Oligoclonal T-Cell Recruitment Within Unstable Plaque. Circulation, 2006, 113, 640-646.	1.6	116
76	C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovascular Research, 2005, 68, 47-55.	1.8	126
77	Targeting Tissue Factor as an Antithrombotic Strategy. Seminars in Vascular Medicine, 2003, 03, 205-214.	2.1	5
78	Role of Tissue Factor Pathway Inhibitor in the Regulation of Tissue Factorâ€Dependent Blood Coagulation. Cardiovascular Drug Reviews, 2002, 20, 67-80.	4.4	22